Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9+ tumors

Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9+ tumors

Relapsed or refractory T acute lymphoblastic leukemia (T-ALL) still carries poor prognosis. Aiming to improve outcomes, the therapeutic potential of an anti-CCR9 monoclonal antibody (mAb 92R), targeting the human chemokine-receptor CCR9 is analyzed on orthotopic xenotransplants. 92R mAb treatment of...

Descripció completa

Dades bibliogràfiques
Autors principals: Silvia Santamaria, Marisa Delgado, Marta Botas, Eva Castellano, Isabel Corraliza-Gorjon, Paloma Lafuente, Cecilia Muñoz-Calleja, Maria L. Toribio, Leonor Kremer, Jose A. Garcia-Sanz
Format: Article
Idioma:English
Publicat: Frontiers Media S.A. 2022-07-01
Col·lecció:Frontiers in Immunology
Matèries:
chemokine receptor CCR9
antitumoral activity
combined chemotherapy and immunotherapy
orthotopic xenograft mouse model
therapeutic antibodies
T-ALL leukemia
Accés en línia:https://www.frontiersin.org/articles/10.3389/fimmu.2022.825635/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.825635/full

Ítems similars